Stefan Zielen1, Jennis Gabrielpillai1, Eva Herrmann2, Johannes Schulze1, Ralf Schubert1, Martin Rosewich1. 1. Department for Children & Adolescents, Division of Allergology, Pulmonology & Cystic fibrosis, Children's Hospital, Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany. 2. Department of Biostatistics, Goethe University, Frankfurt am Main, Germany.
Abstract
BACKGROUND: Ultra-short course pollen immunotherapy adjuvanted with monophosphoryl lipid A (MPL) is attractive to conventional allergen-specific immunotherapy (AIT). Long term efficacy of MPL-AIT has not been evaluated. METHODS: 68 patients (age 16.75 ± 5.3 years) with allergic rhinitis to grass pollen were investigated. Group 1: 21 controls; Group 2: 19 after complete AIT, and Group 3: 28 with AIT and treatment cessation: 4 years range 3-6 years ago. RESULTS: The clinical symptoms (running nose, sneezing, conjunctivitis and the weekly overall score) were significantly reduced in patients group 2 and 3 compared with controls without AIT p < 0.0001. T-regulatory cells and TH1/TH2 cytokine pattern did not differ between patient groups. CONCLUSION: The patients in our trial with grass pollen allergy exhibited significant and long-lasting improvements after MPL-AIT, however larger trials are needed to support this finding.
BACKGROUND: Ultra-short course pollen immunotherapy adjuvanted with monophosphoryllipid A (MPL) is attractive to conventional allergen-specific immunotherapy (AIT). Long term efficacy of MPL-AIT has not been evaluated. METHODS: 68 patients (age 16.75 ± 5.3 years) with allergic rhinitis to grass pollen were investigated. Group 1: 21 controls; Group 2: 19 after complete AIT, and Group 3: 28 with AIT and treatment cessation: 4 years range 3-6 years ago. RESULTS: The clinical symptoms (running nose, sneezing, conjunctivitis and the weekly overall score) were significantly reduced in patients group 2 and 3 compared with controls without AIT p < 0.0001. T-regulatory cells and TH1/TH2 cytokine pattern did not differ between patient groups. CONCLUSION: The patients in our trial with grass pollen allergy exhibited significant and long-lasting improvements after MPL-AIT, however larger trials are needed to support this finding.
Authors: Isabella Anna Joubert; Mark Geppert; Litty Johnson; Robert Mills-Goodlet; Sara Michelini; Evgeniia Korotchenko; Albert Duschl; Richard Weiss; Jutta Horejs-Höck; Martin Himly Journal: Front Immunol Date: 2020-06-30 Impact factor: 7.561
Authors: S Zielen; P Kuna; W Aberer; S Lassmann; O Pfaar; L Klimek; A Wade; K Kluehr; J Raab; D Wessiepe; D Lee; M F Kramer; K Gunawardena; T Higenbottam; M D Heath; M A Skinner; P J de Kam Journal: World Allergy Organ J Date: 2019-10-25 Impact factor: 4.084
Authors: Sviatlana Starchenka; Matthew D Heath; Alyson Lineberry; Tim Higenbottam; Murray A Skinner Journal: World Allergy Organ J Date: 2019-11-16 Impact factor: 4.084
Authors: José Fernando Florido-López; Carmen Andreu-Balaguer; Carmelo Escudero; Marta Seoane-Rodríguez; Mercedes Hernández; Luis Ángel Navarro-Seisdedos; Miguel Torrecillas-Toro; Mónica Anton-Girones; Leticia Herrero-Lifona; Dorimar Brugaletta; Jesús Macías; Rafael Pineda; Maria Ángeles Lara; Julián López-Caballero; Maria José Rojas Journal: World Allergy Organ J Date: 2020-12-18 Impact factor: 4.084
Authors: Gandhi F Pavón-Romero; Maria Itzel Parra-Vargas; Fernando Ramírez-Jiménez; Esmeralda Melgoza-Ruiz; Nancy H Serrano-Pérez; Luis M Teran Journal: Cells Date: 2022-01-08 Impact factor: 6.600